INVITED REVIEW
Role of vascular endothelial growth factor in regulation of physiological angiogenesis

Napoleone Ferrara

Department of Molecular Oncology, Genentech, Inc., South San Francisco, California 94080


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

Evidence accumulating over the last decade has established the fundamental role of vascular endothelial growth factor (VEGF) as a key regulator of normal and abnormal angiogenesis. The biological effects of VEGF are mediated by two tyrosine kinase receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2). The signaling and biological properties of these two receptors are strikingly different. VEGF is essential for early development of the vasculature to the extent that inactivation of even a single allele of the VEGF gene results in embryonic lethality. VEGF is also required for female reproductive functions and endochondral bone formation. Substantial evidence also implicates VEGF as an angiogenic mediator in tumors and intraocular neovascular syndromes, and numerous clinical trials are presently testing the hypothesis that inhibition of VEGF may have therapeutic value.

endothelium; apoptosis; tyrosine kinases; tumor growth; retinopathy


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

THE DEVELOPMENT OF A VASCULAR SUPPLY is essential not only for organ development and differentiation during embryogenesis but also for wound healing and reproductive functions in the adult (35). Angiogenesis is also implicated in the pathogenesis of a variety of disorders: proliferative retinopathies, age-related macular degeneration, tumors, rheumatoid arthritis, and psoriasis (35, 41).

Over the last decade, extensive work has been done on members of the vascular endothelial growth factor (VEGF) gene family. There is strong evidence that this family plays a fundamental role in the growth and differentiation of vascular as well as lymphatic endothelial cells. This family includes several members including VEGF, placenta growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D, and two VEGF-like proteins encoded by two strains of the parapoxvirus orf virus (29, 33, 64). In particular, VEGF (68), referred to also as VEGF-A, is a major regulator of normal and abnormal angiogenesis, including that associated with tumors and several intraocular syndromes (2, 3, 62). VEGF inhibitors are being currently tested in numerous clinical trials (30). For a comprehensive review of the molecular properties and clinical applications of VEGF and other members of the VEGF gene family, refer to several recent review articles (29, 30, 64, 78, 82, 110). This article mainly focuses on the basic biology of VEGF and its receptors and on their role in the regulation of physiological angiogenesis.


    BIOLOGICAL EFFECTS OF VEGF
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

VEGF is a mitogen for vascular endothelial cells derived from arteries, veins, and lymphatics (17, 33, 34, 87). VEGF also elicits a pronounced angiogenic response in a wide variety of in vivo models (68, 87). There is also strong evidence that VEGF is a survival factor for endothelial cells, both in vitro and in vivo (4, 11, 42, 44, 115). VEGF withdrawal has been shown to result in regression of vasculature in several physiological and pathological circumstances. It has been proposed that pericyte coverage is the critical event that determines whether endothelial cells require VEGF for survival in vivo (10). Consistent with a prosurvival activity, VEGF induces expression of the antiapoptotic proteins Bcl-2 and A1 in human endothelial cells (42). Also, the prosurvival activity of VEGF requires the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt signal transduction pathway (44).

Recent studies have reported mitogenic effects of VEGF also on a few non-endothelial cell types in culture, such as retinal pigment epithelial cells (52), pancreatic duct cells (79), and Schwann cells (104). It remains to be established whether this is also true in vivo.

VEGF is known also as vascular permeability factor (VPF) on the basis of its ability to induce vascular leakage in the guinea pig skin (25, 96). These early studies focused on protein extravasation. More recently, Bates and Curry (7) showed that VEGF also induces an increase in hydraulic conductivity of isolated microvessels and that such an effect is mediated by increased calcium influx (8). Other studies have suggested that another important role of VEGF in the regulation of microvascular permeability is the induction of a fenestrated phenotype in at least certain endothelial cells (28, 92, 93).

Dvorak (24) proposed that an increase in microvascular permeability to proteins is a crucial step in angiogenesis. According to this hypothesis, leakage of plasma proteins and formation of an extravascular fibrin gel would be sufficient for endothelial cell growth; the role of mitogenic growth factors would be primarily to augment this process (26). This hypothesis has been tested recently by Eliceiri et al. (27). According to these authors, Src activity is required for VEGF-dependent activities. Members of the Src family appear to be differentially involved in mediating VEGF-dependent permeability vs. angiogenesis (27). Mice deficient in src or yes showed no VEGF-induced vascular permeability, while fyn-/- mice displayed a normal permeability response. However, mice deficient in any of these kinases did not show any defect in VEGF-mediated angiogenesis, suggesting that this function requires multiple members of the Src kinase family. In contrast, the vascular permeability-enhancing activity of VEGF specifically depends on src or yes (27). Because mice lacking src and yes not only have a normal angiogenic response to exogenous VEGF but also develop normally, the conclusion is that enhanced vascular permeability is not a requirement for VEGF-dependent angiogenesis.


    VEGF ISOFORMS
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

By alternative exon splicing of a single gene consisting of eight exons (108), several VEGF isoforms can be generated. Initially, four human VEGF isoforms were described: VEGF121, VEGF165, VEGF189, and VEGF206 (55, 68, 99, 108). Mouse and rat VEGF isoforms are shorter by one amino acid (17, 33). More recently, several additional isoforms have been reported, including VEGF145 (88) and VEGF183 (57), representing less frequent splice variants. VEGF121 is weakly acidic and fails to bind to heparin, while VEGF165 is a basic, heparin-binding protein (56). VEGF189 and VEGF206 are more basic and bind to heparin with even greater affinity than VEGF165 (56). VEGF121 is a freely diffusible protein; VEGF165 is also secreted, although a significant fraction remains bound to the cell surface and the extracellular matrix (ECM). In contrast, VEGF189 and VEGF206 are almost completely sequestered in the ECM (85). However, these isoforms may be released in a soluble form by heparin or heparinase, suggesting that their binding site is represented by proteoglycans containing heparin-like moieties. The long forms may be released also by plasmin following cleavage at the COOH terminus (60). These findings suggest that the VEGF proteins may become available to endothelial cells by at least two different mechanisms: as freely diffusible proteins (VEGF121, VEGF165) or following protease activation and cleavage of the longer isoforms. However, loss of heparin binding, whether due to alternative splicing of RNA or plasmin cleavage, results in a substantial loss of mitogenic activity for vascular endothelial cells (60). In agreement with such conclusions, a very recent study has shown that only VEGF164 is able to fully rescue a tumorigenic phenotype in VEGF-/- cells (51). VEGF120 partially rescued and VEGF188 failed completely to rescue tumor expansion, indicating that VEGF164/165 has optimal characteristics of bioavailability combined with high biological potency. Recent studies have demonstrated that VEGF121 fails to bind neuropilin-1, an isoform-specific VEGF receptor that presents VEGF165 to its signaling receptors in a manner that enhances the effectiveness of the signal transduction cascade, providing a further explanation for the lower bioactivity of VEGF121 relative to that of other isoforms (103). Table 1 summarizes the properties of the VEGF isoforms.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Properties of the principal VEGF isoforms

Other studies have suggested that VEGF isoforms also play a differential role in the development of hemorrhage associated with brain tumors (16). Overexpression of VEGF121 or VEGF165 but not of VEGF189 resulted in significant intracerebral bleeding, suggesting again an important biological difference among the VEGF isoforms (16).


    VEGF RECEPTORS
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2) Tyrosine Kinases

Binding characteristics and structural properties. The Flt-1 (fms-like tyrosine kinase) (23) and KDR (kinase domain region) (107) receptors bind VEGF with high affinity. Both Flt-1 and Flk-1/KDR have seven immunoglobulin (Ig)-like domains in the extracellular domain, a single transmembrane region, and a tyrosine kinase (TK) domain, which is interrupted by a kinase-insert domain (74, 98, 106). Flt-1 has the highest affinity for recombinant human VEGF165, with a dissociation constant (Kd) of ~10-20 pM (23). KDR has a lower affinity for VEGF, with a Kd of ~75-125 pM (107). As indicated in Signal transduction, there is compelling evidence that KDR is the key signaling receptor, while Flt-1 functions, at least in some circumstances, as a decoy receptor. A cDNA coding an alternatively spliced soluble form of Flt-1 (sFlt-1), lacking the seventh Ig-like domain, transmembrane sequence, and cytoplasmic domain, has been identified in human umbilical vein endothelial cells (HUVEC) (58, 59).

Previous studies have mapped the binding site for VEGF to the second Ig-like domain of Flt-1 and KDR (5, 20, 39). Deletion of the second domain of Flt-1 abolished the binding of VEGF. Introduction of the second domain of KDR into an Flt-1 mutant lacking the homologous domain restored VEGF binding (20, 21). However, the ligand specificity was characteristic of the KDR receptor, since the mutant failed to bind PlGF. Wiesmann et al. (113) solved the crystal structure of a VEGF-Flt-1 domain 2 complex. These studies have shown domain 2 in a predominantly hydrophobic interaction with the poles of the VEGF dimer.

Signal transduction. Several studies have demonstrated that Flt-1 and KDR have different signal transduction properties (95, 112). Porcine aortic endothelial cells devoid of VEGF receptors display chemotaxis and mitogenesis in response to VEGF when transfected with a plasmid coding for KDR but not Flt-1 (112). Flk-1/KDR undergoes strong ligand-dependent tyrosine phosphorylation in intact cells, while Flt-1 reveals a weak or undetectable response (95, 112). In further support of this conclusion, VEGF mutants that bind selectively to Flk-1/KDR are able to induce mitogenesis and chemotaxis in normal endothelial and angiogenesis, as well as permeability, in vivo (46, 61). In contrast, Flt-1-selective VEGF mutants are devoid of such activities (46, 61). Also, anti-idiotypic antibodies that activate Flk-1/KDR promote tumor angiogenesis (83). Furthermore, Flk-1/KDR activation has been shown to be required for the antiapoptotic effects of VEGF for HUVEC in serum-free conditions (44). These findings agree with those of other studies showing that PlGF, which binds with high affinity to Flt-1 but not to Flk-1/KDR (Table 2), lacks direct mitogenic or permeability-enhancing properties or the ability to effectively stimulate tyrosine phosphorylation in endothelial cells (84). Interestingly, high concentrations of PlGF expected to saturate the Flt-1 sites are able to potentiate the activity of VEGF, both in vivo and in vitro (84). These findings led to the hypothesis that Flt-1 may not be primarily a signaling receptor but, rather, a "decoy" receptor, able to regulate the activity of VEGF on the vascular endothelium in a negative fashion by sequestering and rendering this ligand less available to Flk-1/KDR (84). Recent studies have provided more evidence in support of this hypothesis. Hiratsuka et al. (54) showed that a targeted mutation resulting in a Flt-1 receptor lacking the TK domain but able to bind VEGF does not result in lethality or any defect in embryonic development and angiogenesis in mice, while complete inactivation of the receptor results in early embryonic lethality (see Embryonic and early postnatal development). Furthermore, endothelial cells isolated from Flt-1(TK-/-) animals display a normal mitogenic response to VEGF. These results suggest that Flt-1 plays its main role in angiogenesis as a ligand-binding molecule, rather than as a signal transducing receptor, at least as defined by conventional criteria. Interestingly, recent studies have shown that the juxtamembrane region of Flt-1 contains a repressor sequence that constitutively inhibits VEGF-dependent signal transduction (47). Deletion of such a repressor sequence confers on Flt-1 the ability to mediate VEGF-dependent endothelial cell migration and PI 3'-kinase activation (47). Recently, Ogawa et al. (80) isolated a polypeptide with ~25% amino acid identity to mammalian VEGF, encoded by a gene previously identified in the genome of orf virus, a parapoxvirus that affects sheep, goats, and, occasionally, humans. This polypeptide, VEGF-E, is a potent mitogen and permeability-enhancing factor. Interestingly, VEGF-E binds Flk-1/KDR (Table 2) and induces its autophosphorylation to almost the same extent as VEGF165 but fails to bind Flt-1 (75, 80). Together, these studies strongly support the hypothesis that, while the role of Flt-1 in the adult vasculature is still unclear, interaction with Flk-1/KDR is essential to induce the full spectrum of VEGF biological responses. Nevertheless, several studies indicated that Flt-1 is able to interact with various signal transducing proteins, including the p85 subunit of the PI 3-kinase and the mitogen-activated protein kinase, and in some circumstances generates a mitogenic signal, at least in transfected cell lines (19, 67, 112).

                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Binding of VEGF family members to the known VEGF tyrosine kinase receptors

Soker et al. (103) demonstrated the existence of an additional VEGF receptor that binds VEGF165 but not VEGF121. This isoform-specific VEGF receptor is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that regulates neuronal cell guidance (40). When coexpressed in cells with KDR, neuropilin-1 enhanced the binding of VEGF165 to KDR and VEGF165-mediated chemotaxis. Conversely, inhibition of VEGF165 binding to neuropilin-1 inhibits its binding to KDR and its mitogenic activity for endothelial cells. These findings suggest that neuropilin-1 may present VEGF165 to the KDR receptor in a manner that enhances the effectiveness of KDR-mediated signal transduction. So far there is no evidence that neuropilin-1 signals after VEGF binding. As previously mentioned, these findings may contribute to the explanation of the greater mitogenic potency of VEGF165 compared with VEGF121. Migdal et al. (77) showed that PlGF-2, a heparin-binding isoform of PlGF (71), also binds to neuropilin-1.

Role of VEGF and Its Receptors in Physiological Angiogenesis

Embryonic and early postnatal development. Gene targeting studies have demonstrated that both Flt-1 and Flk-1/KDR are essential for development of the embryonic vasculature in mice (36, 97). However, their respective roles in endothelial cell proliferation and differentiation appear to be distinct. Mouse embryos homozygous for a targeted mutation in the Flt-1 locus died in utero between days 8.5 and 9.5 (36). Endothelial cells developed in both embryonic and extraembryonic sites but failed to organize in normal vascular channels. More recent studies have shown that an excessive proliferation of endothelial progenitors is the main factor leading to disorganization (37). As previously noted, more recent studies revealed that normal blood vessel development and survival may occur in the absence of the TK domain of Flt-1 (54). Flk-1-/- mice lacked vasculogenesis and also failed to develop blood islands. Hematopoietic precursors were severely disrupted and organized blood vessels failed to develop throughout the embryo or the yolk sac, resulting in death in utero between days 8.5 and 9.5 (97).

Two independent studies (14, 31) have generated direct evidence for the role played by VEGF in embryonic vasculogenesis and angiogenesis. Inactivation of a single VEGF allele in mice resulted in embryonic lethality between days 11 and 12. The VEGF+/- embryos were growth retarded and also exhibited a number of developmental anomalies. The forebrain region appeared significantly underdeveloped. In the heart region, the outflow region was grossly malformed; the dorsal aortas were rudimentary, and the thickness of the ventricular wall was markedly decreased. The yolk sac revealed a markedly reduced number of nucleated red blood cells within the blood islands. Significant defects in the vasculature of other tissues and organs, including the placenta and nervous system, were observed. In situ hybridization demonstrated the expression of VEGF mRNA in heterozygous embryos. Thus the VEGF+/- phenotype is due to gene dosage and not maternal imprinting.

More recently, Carmeliet et al. (15) reported an isoform-specific knockout of the VEGF gene. They generated mice that express exclusively VEGF120. Fifty percent of the VEGF120/120 mice died shortly after delivery, while the remainder died within 2 wk. The survivors demonstrated impaired myocardial contractility, heart enlargement, and defective angiogenesis leading to ischemic cardiomyopathy. These findings suggest that the action of the heparin-binding isoforms of VEGF cannot be replaced by VEGF120.

To selectively investigate the role of VEGF in the heart, a heart-specific VEGF knockout was performed (48). Using Cre-loxP technology, mice with cardiomyocyte-specific deletion of exon 3 in the gene encoding VEGF were generated. Cardiomyocytes represent less than one-third of the total cell number in the heart, yet knockout mice had reduced body weights, and their hearts were thin walled, dilated, and hypovascular and displayed definitive basal contractile dysfunction. Furthermore, the hearts of these mice had fewer coronary microvessels, thinned ventricular walls, depressed basal contractile function, induction of hypoxia-responsive genes, and an abnormal response to beta -adrenergic stimulation. These findings establish a critical role for the cardiomyocyte as a secretory cell.

To determine the role of VEGF in postnatal development, two independent strategies were employed. Inducible, Cre-loxP-mediated gene targeting or administration of a soluble VEGF receptor chimeric protein [mFlt(1-3)-IgG] was used to inactivate VEGF in early postnatal life (43). Mice containing the "floxed" VEGF allele were bred to a strain transgenic for Cre recombinase controlled by an interferon-inducible promoter (MX-1) (65). Partial inhibition of VEGF achieved by this inducible gene targeting system resulted in increased mortality, stunted body growth, and impaired organ development, most notably of the liver. Administration of mFlt(1-3)-IgG, which achieves a higher degree of VEGF inhibition, resulted in nearly complete growth arrest when the treatment was initiated at day 1 or day 8 postnatally. Such treatment was also accompanied by rapid lethality. Decreased levels of proliferation of various cell types were detected in all organs studied. Ultrastructural analysis documented alterations in endothelial and other cell types. The liver of mFlt(1-3)-IgG-treated neonates had fewer endothelial cells and focal loss of integrity of the space of Disse. Histological and biochemical changes consistent with liver and renal failure were observed. Endothelial cells isolated from the liver of mFlt(1-3)-IgG-treated neonates demonstrated an increased apoptotic index, indicating that VEGF is required not only for proliferation but also for survival of endothelial cells. Furthermore, these findings are consistent with a critical dependence of glomerular development on VEGF (63, 102, 109). However, VEGF inhibition resulted in less significant alterations as the animal matured, and the dependence on VEGF was eventually lost sometime after the fourth postnatal week. Administration of mFlt(1-3)-IgG to juvenile mice failed to induce apoptosis in liver endothelial cells (43).

Endochondral bone formation. Endochondral bone formation is a fundamental mechanism for longitudinal bone growth during vertebrate development (89). Cartilage, an avascular tissue, is replaced by bone in a process termed endochondral ossification. During this process, the epiphysial growth plate undergoes morphogenesis. A region of resting chondrocytes differentiates into a zone of proliferating chondrocytes that then hypertrophies and, finally, undergoes apoptotic cell death, while being replaced by bone. Such a sequence of events relies on the precise coupling of chondrogenesis (cartilage production) with osteogenesis (bone formation). During this process, blood vessel invasion from the metaphysis coincides with mineralization of the ECM, apoptosis of hypertrophic chondrocytes, ECM degradation, and bone formation.

Recently, the role of VEGF in endochondral bone formation was examined. The VEGF mRNA is expressed by hypertrophic chondrocytes in the epiphysial growth plate (13, 45). To determine the functional significance of VEGF, a soluble VEGF receptor was administered systemically to 24-day-old mice (45). After such treatment, blood vessel invasion was almost completely suppressed, concomitant with impaired trabecular bone formation. Recruitment and/or differentiation of chondroclasts, which express gelatinase B/matrix metalloproteinase-9 (111), and resorption of terminal chondrocytes was substantially decreased. Although proliferation, differentiation, and maturation of chondrocytes were apparently normal, resorption of hypertrophic chondrocytes was inhibited, resulting in a three- to sixfold expansion of the hypertrophic chondrocyte zone (45).

Interestingly, a similar, albeit less dramatic, phenotype was obtained when VEGF was deleted in the cartilage of developing mice by means of Cre-loxP-mediated, tissue-specific gene inactivation (53). In this model system, the cartilage specific collagen 2a promoter drives the expression of Cre recombinase, which in turn induces the VEGF knockout. loxP sites were introduced into the genome of mice flanking exon 3 of the mouse VEGF gene (43). In this model, a two- to threefold increase in the number of hypertrophic chondrocytes at embryonic day 17.5 was observed (53).

These findings indicate that VEGF-dependent blood vessels are essential for coupling cartilage resorption with bone formation. Therefore, the vasculature carries the essential cellular and humoral signals required for correct growth plate morphogenesis. However, cessation of the anti-VEGF treatment was followed by capillary invasion, restoration of bone growth, resorption of the hypertrophic cartilage, and normalization of the growth plate architecture. Interestingly, VEGF receptor expression was not localized to only vascular endothelial cells. Osteoblasts strongly expressed Flt-1 but not Flk-1/KDR. In this context, it is interesting to point out that an earlier study (76) found VEGF to have chemotactic effects on bovine osteoblasts. It is tempting to speculate that these effects are mediated by Flt-1. These findings indicate that VEGF-mediated capillary invasion is a critical signal that regulates growth plate morphogenesis and triggers cartilage remodeling.

Female reproductive tract angiogenesis. Follicular growth and the development and endocrine function of the ovarian corpus luteum (CL) are dependent on the proliferation of new capillary vessels (6). Subsequently, the blood vessels regress, suggesting the coordinated action of inducers and inhibitors of angiogenesis in the course of the ovarian cycle (49, 72). Earlier studies suggested the release of angiogenic factors from developing CL (50). Therefore, the identification of the regulators of CL angiogenesis has been the object of intense investigation. Previous studies have shown that the VEGF mRNA is temporally and spatially related to the proliferation of blood vessels in the rat, mouse, and primate ovary and in the rat uterus, suggesting that VEGF may be a mediator of the cyclical growth of blood vessels that occurs in the female reproductive tract (18, 86, 91, 100). Very recently, the availability of an effective inhibitor of rodent VEGF, such as a truncated soluble Flt-1 receptor [mFlt(1-3)-IgG], made it possible to directly test this hypothesis (20, 32). Treatment with mFlt(1-3)-IgG resulted in virtually complete suppression of CL angiogenesis in a rat model of hormonally induced ovulation (32). This effect was associated with inhibition of CL development and progesterone release. Also, failure of maturation of the endometrium was observed, probably reflecting suppression of ovarian steroid production plus a direct inhibition of locally produced VEGF. Areas of ischemic necrosis were demonstrated in the CL of treated animals. However, no effect on the preexisting ovarian vasculature was observed. These findings indicate that VEGF-mediated angiogenesis is essential for CL development and endocrine function. A similar inhibition of CL and uterine angiogenesis has been observed in a toxicological study in cynomolgus monkeys treated with a humanized anti-VEGF monoclonal antibody (rhuMAb VEGF) (94). Furthermore, Fraser et al. (38) recently showed that administration of an anti-VEGF neutralizing antibody also inhibits CL development in the marmoset. Treatment, initiated at the time of ovulation and continued for 3 or 10 days, resulted in blockade of development of the normally extensive capillary bed. Luteal function was also markedly compromised by the treatment. These findings support the notion that VEGF-mediated angiogenesis is essential for luteal function.

Role of VEGF in Pathological Angiogenesis

There is considerable evidence that VEGF is a major tumor angiogenesis factor. The VEGF mRNA is upregulated in a large number of tumor types (for reviews, see Refs. 25 and 33). There is an extensive body of data documenting that inhibition of VEGF activity results in suppression of growth of a wide variety of tumor cell lines in murine models (30, 33, 62). Furthermore, clinical trials in cancer patients are ongoing with several VEGF inhibitors, including a humanized monoclonal antibody (90), and various small molecules inhibiting signal transduction (105, 114).

Diabetes mellitus, occlusion of central retinal vein, or prematurity with subsequent exposure to oxygen can all be associated with intraocular neovascularization (41). By virtue of its regulation by hypoxia (101), VEGF was a potential mediator of such neovascularization. In agreement with this hypothesis, elevations of VEGF levels in the aqueous and vitreous of eyes with proliferative retinopathy have been described (1, 2, 73). In a large series where eye fluids from 164 patients were examined, a strong correlation was found between levels of immunoreactive VEGF in the aqueous and vitreous humors and active proliferative retinopathy associated with diabetes, occlusion of central retinal vein, or prematurity (2).

Neovascularization is a major cause of visual loss also in age-related macular degeneration (AMD), the overall leading cause of blindness (41). Several studies have demonstrated the immunohistochemical localization of VEGF in surgically resected choroidal neovascular membranes from AMD patients (66, 69). These findings suggest a role for VEGF in the progression of AMD-related choroidal neovascularization, raising the possibility that a pharmacological treatment with VEGF inhibitors may constitute a therapy for this condition. Clinical trials using a humanized anti-VEGF Fab are ongoing.


    PERSPECTIVES
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

The role of VEGF in developmental and pathological angiogenesis is well documented. However, numerous questions are incompletely answered, including the mechanisms of signal transduction of the VEGF receptors and, in particular, the significance of Flt-1. The recent finding that key signaling functions in Flt-1 are constitutively inhibited by repressor motifs emphasizes the unusual characteristics of this receptor and, furthermore, raises the question as to how such a poorly signaling receptor can play a critical role in the development of the vascular system. This is likely to be the subject of further studies. Also, an important issue is the significance of other members of the VEGF family that selectively bind Flt-1, such as PlGF (84) and VEGF-B (81). In this context, recent studies indicate that VEGF-B inactivation in mice results in reduced heart size and impaired recovery from experimentally induced myocardial ischemia, although the animals develop normally and fail to display any overt deficit (9).

The high expression of VEGF mRNA in human tumors, the presence of the VEGF protein in ocular fluids of individuals with proliferative retinopathies and in the synovial fluid of rheumatoid arthritis patients, and the localization of VEGF in AMD lesions support the hypothesis that VEGF is a key mediator of angiogenesis associated with various disorders. This resulted in extensive clinical testing of such a hypothesis, using a variety of inhibitors (30). The results of phase II studies performed with the use of a humanized anti-VEGF monoclonal antibody in cancer patients have been recently reported (12, 22), and the treatment shows early evidence of clinical efficacy to warrant definitive phase III studies.


    FOOTNOTES

Address for reprint requests and other correspondence: N. Ferrara, Dept. of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080 (E-mail: nf{at}gene.com).


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
BIOLOGICAL EFFECTS OF VEGF
VEGF ISOFORMS
VEGF RECEPTORS
PERSPECTIVES
REFERENCES

1.   Adamis, AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, and Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450, 1994[ISI][Medline].

2.   Aiello, LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen H, Aiello LM, Ferrara N, and King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487, 1994[Abstract/Free Full Text].

3.   Aiello, LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, and Smith LE. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461, 1995[Abstract].

4.   Alon, T, Hemo I, Itin A, Pe'er J, Stone J, and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028, 1995[ISI][Medline].

5.   Barleon, B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, and Martiny-Baron G. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272: 10382-10388, 1997[Abstract/Free Full Text].

6.   Bassett, DL. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 73: 251-278, 1943.

7.   Bates, DO, and Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol Heart Circ Physiol 271: H2520-H2528, 1996[Abstract/Free Full Text].

8.   Bates, DO, and Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca2+-dependent pathway. Am J Physiol Heart Circ Physiol 273: H687-H694, 1997[Abstract/Free Full Text].

9.   Bellomo, D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, and Kay GF. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 86: E29-E35, 2000[ISI][Medline].

10.   Benjamin, L, Hemo I, and Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598, 1998[Abstract/Free Full Text].

11.   Benjamin, LE, Golijanin D, Itin A, Pode D, and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999[Abstract/Free Full Text].

12.   Bergsland, E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WFF, Gaudreault J, Lieberman G, and Kabbinavar F. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer (Abstract). Prog/Proc 36th ASCO Annu Mtg 19: 242, 2000.

13.   Carlevaro, MF, Cermelli S, Cancedda R, and Descalzi Cancedda F. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J Cell Sci 113: 59-69, 2000[Abstract/Free Full Text].

14.   Carmeliet, P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996[ISI][Medline].

15.   Carmeliet, P, Ng Y-S, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard J-C, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA, and Shima DT. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5: 495-502, 1999[ISI][Medline].

16.   Cheng, SY, Nagane M, Huang HS, and Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 94: 12081-12087, 1997[Abstract/Free Full Text].

17.   Conn, G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope DA, and Thomas KA. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 87: 2628-2632, 1990[Abstract].

18.   Cullinan-Bove, K, and Koos RD. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133: 829-837, 1993[Abstract].

19.   Cunningham, SA, Waxham MN, Arrate PM, and Brock TA. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 270: 20254-20257, 1995[Abstract/Free Full Text].

20.   Davis-Smyth, T, Chen H, Park J, Presta LG, and Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 15: 4919-4927, 1996[Abstract].

21.   Davis-Smyth, T, Presta LG, and Ferrara N. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability. J Biol Chem 273: 3216-3222, 1998[Abstract/Free Full Text].

22.   DeVore, R, Herbst RS, Langer CJ, Kelly K, Gaudreault J, Holmgren E, Novotny WF, and Kabbinavar F. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC (Abstract). Prog/Proc 36th ASCO Annu Mtg 19: 485, 2000.

23.   De Vries, C, Escobedo JA, Ueno H, Houck K, Ferrara N, and Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992[ISI][Medline].

24.   Dvorak, HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659, 1986[ISI][Medline].

25.   Dvorak, HF, Brown LF, Detmar M, and Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995[Abstract].

26.   Dvorak, HF, Harvey VS, Estrella P, Brown LF, McDonagh J, and Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57: 673-686, 1987[ISI][Medline].

27.   Eliceiri, BP, Paul R, Schwartzberg PL, Hood JD, Leng J, and Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4: 915-924, 1999[ISI][Medline].

28.   Esser, S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, and Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947-959, 1998[Abstract/Free Full Text].

29.   Ferrara, N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814, 1999[ISI][Medline].

30.   Ferrara, N, and Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364, 1999[ISI][Medline].

31.   Ferrara, N, Carver Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell Braxton L, Hillan KJ, and Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996[ISI][Medline].

32.   Ferrara, N, Chen H, Davis-Smyth T, Gerber H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ, and Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336-340, 1998[ISI][Medline].

33.   Ferrara, N, and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997[Abstract/Free Full Text].

34.   Ferrara, N, and Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858, 1989[ISI][Medline].

35.   Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995[ISI][Medline].

36.   Fong, GH, Rossant J, Gertsenstein M, and Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995[ISI][Medline].

37.   Fong, GH, Zhang L, Bryce DM, and Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126: 3015-3025, 1999[Abstract/Free Full Text].

38.   Fraser, HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, and Bicknell R. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141: 995-1000, 2000[Abstract/Free Full Text].

39.   Fuh, G, Li B, Crowley C, Cunningham B, and Wells JA. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273: 11197-11204, 1998[Abstract/Free Full Text].

40.   Fujisawa, H, and Kitsukawa T. Receptors for collapsin/semaphorins. Curr Opin Neurobiol 8: 587-592, 1998[ISI][Medline].

41.   Garner, A. Vascular diseases. New York: Marcel Dekker, 1994.

42.   Gerber, HP, Dixit V, and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins. Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316, 1998[Abstract/Free Full Text].

43.   Gerber, HP, Hillan KJ, Ryan AM, Kowalski J, Keller G-A, Rangell L, Wright BD, Radtke F, Aguet M, and Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 126: 1149-1159, 1999[Abstract/Free Full Text].

44.   Gerber, HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, and Ferrara N. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343, 1998[Abstract/Free Full Text].

45.   Gerber, HP, Vu TH, Ryan AM, Kowalski J, Werb Z, and Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628, 1999[ISI][Medline].

46.   Gille, H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck T, Peleltier N, and Ferrara N. Analysis of biological effects and signaling properties of Flt-1(VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230, 2001[Abstract/Free Full Text].

47.   Gille, H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, and Ferrara N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J 19: 4064-4073, 2000[Abstract/Free Full Text].

48.  Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P, Gu YY, Hickey R, Nath AK, Dalton N, Peterson L, Ross J, Chien KR, and Ferrara N. A cardiac myocyte VEGF paracrine patheway is required to maintain cardiac function. Proc Natl Acad Sci USA. In press.

49.   Goede, V, Schmidt T, Kimmina S, Kozian D, and Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78: 1385-1394, 1998[ISI][Medline].

50.   Gospodarowicz, D, and Takral TK. Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc Natl Acad Sci USA 75: 847-851, 1978[Abstract].

51.   Grunstein, J, Masbad JJ, Hickley R, Giordano F, and Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinated fashion to recruit and expand tumor vasculature. Mol Cell Biol 20: 7282-7291, 2000[Abstract/Free Full Text].

52.   Guerrin, M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F, and Plouet J. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 164: 385-394, 1995[ISI][Medline].

53.   Haigh, JJ, Gerber HP, Ferrara N, and Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 127: 1445-1453, 2000[Abstract/Free Full Text].

54.   Hiratsuka, S, Minowa O, Kuno J, Noda T, and Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 4: 9349-9354, 1998.

55.   Houck, KA, Ferrara N, Winer J, Cachianes G, Li B, and Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814, 1991[Abstract].

56.   Houck, KA, Leung DW, Rowland AM, Winer J, and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-26037, 1992[Abstract/Free Full Text].

57.   Jingjing, L, Xue Y, Agarwal N, and Roque RS. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 40: 752-759, 1999[Abstract].

58.   Kendall, RL, and Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993[Abstract].

59.   Kendall, RL, Wang G, and Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996[ISI][Medline].

60.   Keyt, BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, and Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271: 7788-7795, 1996[Abstract/Free Full Text].

61.   Keyt, BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, and Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271: 5638-5646, 1996[Abstract/Free Full Text].

62.   Kim, KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993[ISI][Medline].

63.   Kitamoto, Y, Tokunaga H, and Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 99: 2351-2357, 1997[Abstract/Free Full Text].

64.   Korpelainen, EI, and Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 10: 159-164, 1998[ISI][Medline].

65.   Kuhn, R, Schwenk F, Aguet M, and Rajewsky K. Inducible gene targeting in mice. Science 269: 1427-1429, 1995[ISI][Medline].

66.   Kvanta, A, Algvere PV, Berglin L, and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934, 1996[Abstract].

67.   Landgren, E, Schiller P, Cao Y, and Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16: 359-367, 1998[ISI][Medline].

68.   Leung, DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989[ISI][Medline].

69.   Lopez, PF, Sippy BD, Lambert HM, Thach AB, and Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37: 855-868, 1996[Abstract].

70.   Lyttle, DJ, Fraser KM, Flemings SB, Mercer AA, and Robinson AJ. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 68: 84-92, 1994[Abstract].

71.   Maglione, D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei KJ, Chou JY, and Persico MG. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8: 925-931, 1993[ISI][Medline].

72.   Maisonpierre, PC, Suri C, Jones PF, Bartunkova S, Wiegend SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopulos N, Daly TJ, Davis S, Sato TN, and Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997[Abstract/Free Full Text].

73.   Malecaze, F, Clemens S, Simorer-Pinotel V, Mathis A, Chollet P, Favard P, Bayard F, and Plouet J. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112: 1476-1482, 1994[Abstract].

74.   Matthews, W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, and Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88: 9026-9030, 1991[Abstract].

75.   Meyer, M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha HJ, and Dehio C. A novel vascular endothelial growth factor encoded by orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18: 363-374, 1999[Abstract/Free Full Text].

76.   Midy, V, and Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 199: 380-386, 1994[ISI][Medline].

77.   Migdal, M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, and Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273: 22272-22278, 1998[Abstract/Free Full Text].

78.   Neufeld, G, Cohen T, Gengrinovitch S, and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999[Abstract/Free Full Text].

79.   Oberg-Welsh, C, Sandler S, Andersson A, and Welsh M. Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro. Mol Cell Endocrinol 126: 125-132, 1997[ISI][Medline].

80.   Ogawa, S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, and Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273: 31273-31282, 1998[Abstract/Free Full Text].

81.   Olofsson, B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, and Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95: 11709-11714, 1998[Abstract/Free Full Text].

82.   Ortega, N, Hutchings H, and Plouet J. Signal relays in the VEGF system. Front Biosci 4: D141-D152, 1999[Medline].

83.   Ortega, N, Jonca F, Vincent S, Favard C, Ruchoux MM, and Plouet J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am J Pathol 151: 1215-1224, 1997[Abstract].

84.   Park, JE, Chen HH, Winer J, Houck KA, and Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654, 1994[Abstract/Free Full Text].

85.   Park, JE, Keller H-A, and Ferrara N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326, 1993[Abstract].

86.   Phillips, HS, Hains J, Leung DW, and Ferrara N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127: 965-967, 1990[Abstract].

87.   Plouet, J, Schilling J, and Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 8: 3801-3808, 1989[Abstract].

88.   Poltorak, Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, and Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151-7158, 1997[Abstract/Free Full Text].

89.   Poole, AR. Cartilage: Molecular Aspects. Boca Raton, FL: CRC, 1991, p. 179-211.

90.   Presta, LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, and Ferrara N. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997[Abstract].

91.   Ravindranath, N, Little-Ihrig L, Phillips HS, Ferrara N, and Zeleznik AJ. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131: 254-260, 1992[Abstract].

92.   Roberts, WG, and Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108: 2369-2379, 1995[Abstract/Free Full Text].

93.   Roberts, WG, and Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772, 1997[Abstract].

94.   Ryan, AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, and O'Neill CA. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27: 78-86, 1999[ISI][Medline].

95.   Seetharam, L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, and Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10: 135-147, 1995[ISI][Medline].

96.   Senger, DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983[ISI][Medline].

97.   Shalaby, F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, and Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995[ISI][Medline].

98.   Shibuya, M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, and Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 8: 519-527, 1990.

99.   Shima, DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, and D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 271: 3877-3883, 1996[Abstract/Free Full Text].

100.   Shweiki, D, Itin A, Neufeld G, Gitay-Goren H, and Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis. J Clin Invest 91: 2235-2243, 1993[ISI][Medline].

101.   Shweiki, D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992[ISI][Medline].

102.   Simon, M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, and Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol Renal Fluid Electrolyte Physiol 268: F240-F250, 1995[Abstract/Free Full Text].

103.   Soker, S, Takashima S, Miao HQ, Neufeld G, and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998[ISI][Medline].

104.   Sondell, M, Lundborg G, and Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19: 5731-5740, 1999[Abstract/Free Full Text].

105.   Strawn, LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, and Shawver LK. Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545, 1996[Abstract].

106.   Terman, BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, and Shows TB. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6: 1677-1683, 1991[ISI][Medline].

107.   Terman, BI, Dougher Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, and Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586, 1992[ISI][Medline].

108.   Tischer, E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, and Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991[Abstract/Free Full Text].

109.   Tufro-McReddie, A, Norwood VF, Aylor KW, Botkin SJ, Carey RM, and Gomez RA. Oxygen regulates vascular endothelial growth factor-mediated vasculogenesis and tubulogenesis. Dev Biol 183: 139-149, 1997[ISI][Medline].

110.   Veikkola, T, Karkkainen M, Claesson-Welsh L, and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203-212, 2000[Free Full Text].

111.   Vu, TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, and Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422, 1998[ISI][Medline].

112.   Waltenberger, J, Claesson Welsh L, Siegbahn A, Shibuya M, and Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994[Abstract/Free Full Text].

113.   Wiesmann, C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, and de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91: 695-704, 1997[ISI][Medline].

114.   Wood, JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, and Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189, 2000[Abstract/Free Full Text].

115.   Yuan, F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, and Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770, 1996[Abstract/Free Full Text].


Am J Physiol Cell Physiol 280(6):C1358-C1366
0363-6143/01 $5.00 Copyright © 2001 the American Physiological Society